Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor

Abstract

Pazopanib is an effective treatment option for recurrent or metastatic SFT in first- and second-line settings. Liver injury is a major adverse event and adequate treatment withdrawal and dose reduction should be considered when necessary.